BioMarin Pharmaceutical Inc. Discontinues Development of BMN 349

BioMarin Pharmaceutical Inc. announced on December 19, 2025, its decision to discontinue the development of BMN 349, an oral therapeutic intended for the treatment of Alpha-1 antitrypsin deficiency (AATD)-associated liver disease. The company has not provided specific reasons for this decision at this time. This development pertains to a potential treatment for a rare genetic disorder affecting the liver. Further updates on the company's pipeline and strategic decisions are anticipated.